Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 4 3Phase 3 3Phase NA 2Phase 1 2Phase 1/2 1

Status

Recruiting 5Completed 3Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 1

Conditions

Pneumonia 1Breast Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × Adrenal Cortex Hormones × Clear all
NCT00421174 2021-11-01

BMTCTN0403

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
37 enrolled 20 charts

Pneumonia

NCT02046603 2018-12-07

ACT-MOVE

Hoffmann-La Roche

Phase 3 Completed
162 enrolled 30 charts

Arthritis, Rheumatoid

NCT00661102 2016-11-02

A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).

Hoffmann-La Roche

Phase 3 Completed
598 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡